Loading...

VTGN VISTAGEN THERAPEUTICS INC Earnings Reports 8-K Filing

VSTG

VTGN

VISTAGEN THERAPEUTICS INC

(VTGN)

2024 8-K

Summary

Summary

Director Appointment

Management Changes

Financial Statements

Equity Offerings

Product Expansion

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Filing Letter with Quantita...

Filing with Quantitative Data

Filing with Quantitative Data

Quantitative Data

Filing with Quantitative Data

Filing with Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Filing with Quantitative Data

Underwriting Agreement

Quantitative Data

Update on Progress and Fina...

Filing with Quantitative Data

Filing with Quantitative Data

Other Special Situation

Filing Letter with Financia...

Other Special Situation

Filing with Quantitative Data

Financial Update

Filing with Quantitative Data

Quantitative Data

Quantitative Data

Filing with Quantitative Data

Filing with Quantitative Data

Quantitative Data

Other Special Situation

Filing Letter with Quantita...

Other Special Situation

Filing with Quantitative Data

Filing Letter with Quantita...

Update on Clinical Developm...

External Links:

Vistagen Therapeutics Inc reported a net loss of $5.4 million for the quarter ended September 30, 2023, with cash and cash equivalents of $15.2 million as of that date.

AI Assistant

VISTAGEN THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.